<DOC>
	<DOCNO>NCT02339740</DOCNO>
	<brief_summary>This phase III trial study tretinoin arsenic trioxide treat patient newly diagnose acute promyelocytic leukemia . Standard treatment acute promyelocytic leukemia involve high dos common class chemotherapy drug call anthracyclines , know cause long-term side effect , especially heart . Tretinoin may stop growth cancer cell block enzymes need cell growth . Arsenic trioxide may stop growth cancer cell either kill cell , stop dividing , stop spread . Completely remove reduce amount anthracycline chemotherapy give tretinoin together arsenic trioxide may effective treatment acute promyelocytic leukemia may reduce long-term side effect .</brief_summary>
	<brief_title>Tretinoin Arsenic Trioxide Treating Patients With Untreated Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To eliminate exposure conventional chemotherapy ( include anthracyclines ) , patient standard risk acute promyelocytic leukemia ( APL ) , use arsenic trioxide ( ATO ) all-trans retinoic acid ( ATRA ) ( tretinoin ) base therapy achieve event free survival ( EFS ) inferior compare historical control . II . To significantly reduce exposure conventional chemotherapy , particular , anthracycline exposure , patient high risk APL , use ATO ATRA base therapy achieve event free survival inferior compare historical control . SECONDARY OBJECTIVES : I . To analyze clinical impact FMS-like tyrosine kinase 3 ( FLT3 ) mutation pediatric APL . II . To correlate clinical outcome kinetics reduction promyelocytic leukemia ( PML ) /retinoic acid receptor alpha ( RARalpha ) transcript level quantitative reverse transcription-polymerase chain reaction ( RT-PCR ) ( RQ-PCR ) bone marrow peripheral blood sample diagnosis time point therapy . III . To monitor incidence coagulopathy complication , utilize standardized conventional supportive care , correlate battery coagulation test . IV . To evaluate neurocognitive outcome patient treat protocol use patient-completed , performance-based measure neuropsychological function parent questionnaire report . OUTLINE : INDUCTION THERAPY : Patients standard high risk APL receive tretinoin orally ( PO ) twice daily ( BID ) arsenic trioxide intravenously ( IV ) 2-4 hour day 1-28 . High risk APL patient also receive dexamethasone PO IV BID day 1-14 idarubicin hydrochloride IV 15 minute day 1 , 3 , 5 , 7 . Patients achieve hematologic complete remission ( hCR ) /hematologic complete remission incomplete blood count recovery ( hCRi ) may go consolidation therapy . Patients achieve hCR/hCRi may continue treatment tretinoin arsenic trioxide 70 day . CONSOLIDATION THERAPY : Patients receive tretinoin PO BID day 1-14 29-42 arsenic trioxide IV 2-4 hour day 1-5 , 8-12 , 15-19 , 22-26 . Treatment repeat every 56 day 3 course absence disease progression unacceptable toxicity . Patients receive tretinoin PO BID day 1-14 arsenic trioxide IV 2-4 hour day 1-5 , 8-12 , 15-19 , 22-26 . MINIMAL RESIDUAL DISEASE ( MRD ) CONSOLIDATION THERAPY : Patients APL bone marrow 2 course consolidation therapy receive MRD consolidation therapy prior continue onto consolidation course 3 . Patients receive cytarabine IV 1-3 hour every 12 hour day 1-4 ; mitoxantrone hydrochloride IV 15-30 minute day 3-6 ; tretinoin PO BID day 1-14 . If APL cell bone marrow completion MRD consolidation therapy , patient continue consolidation course 3 . After completion study treatment , patient follow monthly 12 month , every 3 month 36 month , every 6 month 48 month , annually 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin A</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Retinol palmitate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients must newly diagnose clinical diagnosis APL ( initially morphology bone marrow peripheral blood ) Bone marrow highly preferred case marrow obtain diagnosis , peripheral blood accept If RQPCR result know time study enrollment , patient must demonstrate PMLRARalpha transcript RQPCR eligible NOTE : A lumbar puncture require order enrol study lumbar puncture recommend time diagnosis ; diagnosis APL know suspect , diagnostic lumbar puncture patient neurologic symptom defer coagulopathy correct ; central nervous system ( CNS ) disease suspect proven , compute tomography ( CT ) magnetic resonance imaging ( MRI ) consider rule possibility associate chloroma ; CNS disease document , patient still eligible receive protocol direct intrathecal treatment Patients may receive maximum 5 day pretreatment ATRA prior administration protocol therapy Treatment hydroxyurea , corticosteroid ( route ) intrathecal cytarabine prior begin protocol direct therapy allow ; however , note lumbar puncture intrathecal therapy initial diagnosis APL recommend All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet Patients secondary APL exclude ; include patient APL may result prior treatment ( chemotherapy radiation ) Patients isolated myeloid sarcoma ( myeloblastoma , chloroma , include leukemia cutis ) without evidence APL bone marrow peripheral blood morphology exclude Patients preexist diagnosis prolong QT syndrome ( even correct QT interval [ QTc ] normal time APL diagnosis ) exclude Patients baseline QTc &gt; 450 msec exclude ; Bazett 's formula use measurement correct QT interval : QT interval ( msec ) divide square root RR interval ( msec ) Patients history presence significant ventricular atrial tachyarrhythmia exclude Patients right bundle branch block plus leave anterior hemiblock , bifascicular block exclude Patients serum creatinine &gt; 3.0 mg/dL patient active dialysis renal dysfunction exclude Patients receive treatment cytotoxic chemotherapy prior begin protocol therapy ( allow criterion ) exclude Female patient pregnant exclude ; patient pregnant plan become pregnant treatment ; pregnancy test prior enrollment require female patient childbearing potential Lactating female plan breastfeed infant exclude Sexually active patient reproductive potential agree abstinent use 2 form effective contraception treatment 1 month therapy exclude</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>